期刊文献+

Nod1受体激活对腹膜间皮细胞自噬相关蛋白表达的影响

Nod1-agonist induced autophagy-related protein expression in rats peritoneal mesothelial cells
下载PDF
导出
摘要 目的探讨Nod1受体激活对腹膜间皮细胞自噬的影响。方法 Nod1受体激动剂iE-DAP作用大鼠原代培养腹膜间皮细胞0、1、2h,Western blot检测微管相关蛋白1轻链3(LC3)、Beclin-1的表达。结果随刺激时间延长,LC3-Ⅱ/LC3-Ⅰ蛋白表达比值增加,Beclin-1蛋白表达亦增加。结论 Nod1受体激活可诱导腹膜间皮细胞自噬的发生,这有可能发挥清除细胞内细菌感染的作用。 Objective To investigate the Nod1-agonist-induced autophagy-related protein expression in rats peritoneal mesothelial cells. Methods Rat peritoneal mesothelial cells in the logarithmic growth phase were cultured. Cells were treated with iE-DAP(Nod1-agonist)at 0h,1h and 2h. Western blot analysis were used to detect the expressions of microtubule-associated protein 1 light chain 3(LC3)and Beclin-1 in cell. Results Compared with the control group,the ratio of LC3-Ⅱ/LC3-Ⅰ and Beclin-1 protein expression increased with the prolongation of iE-DAP stimulation. Conclusion Autophagy of rat peritoneal mesothelial cells can be induced by Nod1-agonist, which may enhance the antibacterial capacity.
出处 《中国现代医药杂志》 2012年第4期6-8,共3页 Modern Medicine Journal of China
基金 2011年广东省医学科学技术研究基金资助(青年项目 编号B2011315)
关键词 Nod1 腹膜间皮细胞 自噬 LC3 Nod1 Peritoneal mesothelial cells Autophagy LC3
  • 相关文献

参考文献14

  • 1Oreopoulos DG,Yang X. Long-term survival on peritoneal dialysis is not a dream anymore:lessons from the East[J].Peritoneal Dialysis International,2007.410-412.
  • 2伍军,阳晓,余学清.腹膜透析与血液透析:哪种透析治疗方式具有更好的生存率?[J].中华肾脏病杂志,2008,24(12):931-933. 被引量:6
  • 3Piraino B. Peritonitis as a complication of peritoneal dialysis[J].Journal of the American Society of Nephrology,1998.1956-1964.
  • 4Fried LF,Bernardini J,Johnston JR. Peritonitis influences mortality in peritoneal dialysis patients[J].Journal of the American Society of Nephrology,1996.2176-2182.
  • 5Kavanagh D,Prescott GJ,Mactier RA. Peritoneal dialysis-associated peritonitis in Scotland (1999-2002)[J].Nephrology Dialysis Transplantation,2004.2584-2591.
  • 6Chen G,Shaw MH,Kim YG. NOD-like receptors:role in innate immunity and inflammatory disease[J].Annu Rev Pathol,2009.365-398.
  • 7Delgado M,Singh S,De Haro S. Autophagy and pattern recognition receptors in innate immunity[J].Immunological Reviews,2009.189-202.
  • 8Kato S,Yuzawa Y,Tsuboi N. Endotoxin-induced chemokine expression in murine peritoneal mesothelial cells:the role of tolllike receptor 4[J].Journal of the American Society of Nephrology,2004,(05):1289-1299.
  • 9Wu J,Yang X,Zhang YF. Angiotensin Ⅱ upregulates Tolllike receptor 4 and enhances lipopolysaccharide-induced CD4O expression in rat peritoneal mesothelial cells[J].Inflammation Research,2009.473-482.
  • 10Wu J,Yang X,Zhang YF. Glucose-based peritoneal dialysis fluids downregulates TLR and triggers hyporesponsiveness to pathogen-associated molecular patterns in human peritoneal mesothelial cells[J].Clinical and Vaccine Immunology,2010,(05):757-763.

二级参考文献31

  • 1Wright CC, Sim J, Intention-to-treat approach to data from randomized controlled trials: a sensitivity analysis. J Clin Epidemiol, 2003, 56: 833-842.
  • 2Xue JL, Chen SC, Ebben JP, et al. Peritoneal and hemodialysis: Ⅰ. Differences in patient characteristics at initiation. Kidney Int, 2002, 61: 734-740.
  • 3Ganesh SK, Hulbert-Shearon T, Port FK, et al. Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J Am Soc Nephrol, 2003, 14: 415-424.
  • 4Stack AG, Molony DA, Rahman NS, et al. Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States. Kidney Int, 2003, 64: 1071-1079.
  • 5Lo WK. Peritoneal dialysis utilization and outcome: what are we facing? Perit Dial Int, 2007, 27 Suppl 2: S42-S47.
  • 6Finkelstein FO. Structural requirements for a successful chronic peritoneal dialysis program. Kidney Int Sppul, 2006, (103): S118-S121.
  • 7Burkart J, Piraino B, Kaldas H, et al. Why is the evidence favoring hemodialysis over peritoneal dialysis misleading? Semin Dial, 2007, 20: 200-202.
  • 8U.S. Renal Data System: USRDS 2005 Annual Data Report: Atlas of End- Stage Renal Disease in the United States. Bethesda,MD: National Institutes of Health,National Institute of Diabetes and Digestive and Kidney Disease 2005.
  • 9Sehulman G. Mortality and treatment modality of end-stage renal disease. Ann Intern Med, 2005, 143: 229-231.
  • 10Vonesh EF, Snyder JJ, Foley RN, et al. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int, 2004, 66: 2389-2401.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部